4
Changes in Ownership
Allogene Therapeutics, Inc. Filed Acc 0001209191-19-034861
Chief Technical Officer sold 48,828 shares at an average $26.76 ($1,306,774)
- Chief Technical Officer acquired 48,828 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| MOORE ALISON Chief Technical Officer | 2019-06-03 | Option exercise | +48,828 | $2.27 | $110,840 | 86,385 | D |
| MOORE ALISON Chief Technical Officer | 2019-06-03 | Sale | −47,205 | $26.74 | $1,262,455 | 39,180 | D |
| MOORE ALISON Chief Technical Officer | 2019-06-03 | Sale | −1,623 | $27.31 | $44,319 | 37,557 | D |
| Derivatives | |||||||
| MOORE ALISON Chief Technical Officer | 2019-06-03 | Option exercise · Option to Purchase Common Stock (Right to Buy) | −48,828 | 843,672 | D | ||
| Open-market sales · 48,828 sh · avg $26.76 · $1,306,774 | |||||||
Loading xslF345X03/doc4.xml…